Description: Heart and blood vessels as targets organs of xenobiotics: an overview (S.P. Bishop, W.D. Kerns). Cardiac development: prospects for a morphologically integrated molecular approach (F. de Jong, A. Moorman, S. Virgh). Myofilament-based mechanisms of myocardial contraction and their assessment (K.B. Campbell, B.K. Slinker). Molecular pharmacology of arterial endothelium and smooth muscle cells (G.Z. Feuerstein, D.W. Kerns). Molecular pharmacology of cardiac muscle cells (H.M. Colecraft, S.-S. Sheu). Morphologic evaluation of the heart and blood vessels (S.P. Bishop, C. Louden). Electrocardiography in toxicology studies (D.K. Detweiler). Use of echocardiography and bioimpedance in preclinical drug assessment (D.H. Knight, A.A. Fossa, M.J. DePasquale). Functional evaluation of the cardiovascular system utilizing instrumented animal models (R.D. Sarazan). Use of magnetic resonance imaging for evaluation of myocardial function and structure in the intact animal (L. Dell'Italia, S.P. Bishop). In vitro evaluation of cardiac and myocyte function (D. Acosta Jr, A.B. Combs, S. Pan, E. Chacon). Elucidation of pathogenic mechanisms of vascular injury and toxicity using in vitro cell culture systems (K.S. Ramos). Use of transgenic animals in cardiovascular toxicity testing (M. Franklin, L.J. Field). Endothelial and smooth muscle cell injury and repair in contrived models and natural disease (E.A. Sprague). Hemodynamic influences on vascular injury, repair and remodeling (D. Ku, R. Nerem). Biochemical and molecular mechanism of myocardial injury (M. Karmazyn, J.R. Bend). Pathogenesis of arterial lesions caused by vasoactive compounds in laboratory animals (E.C. Joseph, W.D. Kerns, G.M. Mesfin). Pathogenesis of chemically induced arterial lesions (P.J. Boor, S.D. Langford). Characterization of myocardial toxicity caused by agents that affect the myocyte (V.J. Ferrans, J.F. VanVleet). Pathogenesis and characterisation of myocardial lesions caused by vasoactive compounds (G.E. Sandusky). Agents associated with the development of cardiac hypertrophy and/or congestive heart failure (A.L. Metz, A. W. Gough, D.G. Robertson, F.A. de la Iglesia, S.P. Bishop). Inflammatory mechanisms (B.M. McManus, S. Wood). Trichlorethylene and its potential as a cardiac teratogen (P.D. Johnson, B.V. Dawson, R.B. Runyan). Characterization of toxic and drug-induced cardiovascular lesions in humans (A. Burke, F.G. Mullick, R. Virmani). Managing cardiovascular risk in phase 1 (D.K. Jorkasky, M.I. Freed, B. E. Ilson)

Please Wait